What is LivaNova's market cap?

LivaNova (LIVN) has a market capitalization of $4.4B and trades on NASDAQ.

What is LivaNova's revenue and profitability?

LivaNova generated $1.4B in trailing twelve-month revenue with a net loss of $251.1M, representing a net margin of -16.1%. Gross margin stands at 67.5%, with free cash flow of $161.0M. These figures are based on the Q1 2026 filing.

Who are LivaNova's competitors?

LivaNova's key competitors include Medtronic plc, NeuroPace, Inc., Inspire Medical Systems, and others. These companies compete in similar markets and product categories.

Who does LivaNova partner with?

LivaNova's notable partners include Centers for Medicare & Medicaid Services.

What subsidiaries does LivaNova have?

LivaNova's subsidiaries include ImThera Medical.

Where is LivaNova headquartered?

LivaNova is headquartered in United Kingdom and employs approximately 2,900 people. It has been publicly traded since 1993.

LivaNova

LIVN

LivaNova is a global medical technology company that develops and manufactures innovative solutions for cardiovascular and neurological conditions.

Market cap

$4.43B+84.5%

Revenue$1.4B+12.4%

Net income-$251.1M-497%

Free cash flow$161.0M+10.7%

EPS (diluted)-$4.62-502%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$362.3MBeat by $16.2M EPS$0.98Beat by $0.13

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$380.5M

EPS estimate$1.08

Financials

Q1 2026

Income statement

See full

Revenue$362.3M+14.3%

Gross profit$243.7M+12.7%

Operating income$41.5M-14.7%

Net income$22.3M+107%

EPS (diluted)$0.40+107%

Balance sheet

See full

Cash & equivalents$539.7M-26.9%

Total debt$340.9M-49.7%

Total equity$1.2B+17.1%

Total assets$2.5B-1.7%

Cash flow

See full

Operating cash flow$15.2M-36.5%

CapEx$14.3M+32.4%

Free cash flow$926.0K-93.0%

Valuation & ratios

Valuation

See full

Market cap$4.43B+84.5%

Enterprise value$4.23B+87.2%

P/S3.1×+1.3×

Profitability

See full

Gross margin67.5%-0.5pp

Operating margin13.4%+0.8pp

FCF margin11.2%-0.2pp

Returns & leverage

See full

Debt / equity0.3×-0.4×

Current ratio1.3×-0.2×

Segments

By segment

See full

Cardiopulmonary$208.7M+18.3%

Neuromodulation$151.8M+9.3%

By geography

See full

Rest of World$101.9M+15.8%

Europe$75.7M+26.7%

Competitors

By market cap

Abbott$182.00B-17.2%

Medtronic$107.81B-8.5%

LivaNova$4.4B+86.8%

Haemonetics$3.6B+1.2%

ITG

Integer Holdings$3.4B-10.9%

Inspire Medical Systems$1.5B-61.9%

Neuropace, Inc.$521.6M+82.0%

Neuraxis$83.5M+223%

By revenue growth

Neuropace, Inc.+18.1%

LivaNova+12.4%

Inspire Medical Systems+8.9%

Medtronic+8.4%

Abbott+8.1%

ITG

Integer Holdings+6.3%

Haemonetics-2.0%

By net margin

Inspire Medical Systems14.33%+6.4pp

Integer Holdings7.64%+3.2pp

LivaNova-16.12%-22.5pp

Neuropace, Inc.-21.67%+7.8pp

Profile

LivaNova is a global medical technology company that develops and manufactures innovative solutions for cardiovascular and neurological conditions. The company focuses on life-saving therapies for patients undergoing cardiac surgery and those suffering from drug-resistant epilepsy and depression. Its core value proposition centers on improving patient outcomes through advanced neuromodulation devices and comprehensive cardiopulmonary systems.

Competitive position

LivaNova is a market leader in cardiopulmonary and neuromodulation therapies, maintaining its position through continuous R&D and a global distribution network.

GeographiesUnited States, Europe, Brazil, Italy, Germany, Australia

Customer segmentsHospitals, Specialized Healthcare Providers, Medical Institutions

Business modelManufacturing, Direct Sales, Research and Development

SuppliersRaw material suppliers, Electronic component manufacturers, Specialized medical tubing suppliers, Software and AI developers

CustomersHospitals, Surgical centers, Independent medical distributors, Government healthcare programs (Medicare/Medicaid)

CountryUnited Kingdom

Listed1993

Employees2.9K

CEOVladimir A. Makatsaria

SectorHealthcare

IndustryMedical - Devices

Websitelivanova.com

FilingsSEC EDGAR

Ask your AI about LivaNova.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is LivaNova's market cap?: LivaNova (LIVN) has a market capitalization of $4.4B and trades on NASDAQ.
What is LivaNova's revenue and profitability?: LivaNova generated $1.4B in trailing twelve-month revenue with a net loss of $251.1M, representing a net margin of -16.1%. Gross margin stands at 67.5%, with free cash flow of $161.0M. These figures are based on the Q1 2026 filing.
Who are LivaNova's competitors?: LivaNova's key competitors include Medtronic plc, NeuroPace, Inc., Inspire Medical Systems, and others. These companies compete in similar markets and product categories.
Who does LivaNova partner with?: LivaNova's notable partners include Centers for Medicare & Medicaid Services.
What subsidiaries does LivaNova have?: LivaNova's subsidiaries include ImThera Medical.
Where is LivaNova headquartered?: LivaNova is headquartered in United Kingdom and employs approximately 2,900 people. It has been publicly traded since 1993.